CD274 and metastatic neoplasm: By virtue of hypoxia mitigation, immunosuppressive microenvironment remodeling and PD-L1 upregulation-enabled therapy combined with anti-PD-L1 therapy, the IRT radiosensitizers are equipped with the most robust antitumor activity against primary and metastatic tumors in vivo, which holds high potential for clinical translation.